0000899243-23-016491.txt : 20230626
0000899243-23-016491.hdr.sgml : 20230626
20230626164619
ACCESSION NUMBER: 0000899243-23-016491
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230622
FILED AS OF DATE: 20230626
DATE AS OF CHANGE: 20230626
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Session R.A. II
CENTRAL INDEX KEY: 0001701846
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 231042937
MAIL ADDRESS:
STREET 1: C/O AVEXIS, INC.
STREET 2: 2275 HALF DAY ROAD, SUITE 200
CITY: BANNOCKBURN
STATE: IL
ZIP: 60015
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-22
0
0001806310
Taysha Gene Therapies, Inc.
TSHA
0001701846
Session R.A. II
7318 MORTON STREET
DALLAS
TX
75209
0
0
1
0
0
Common Stock
2023-06-22
4
S
0
10508
0.7027
D
8975719
D
Common Stock
2023-06-23
4
S
0
18100
0.7036
D
8957619
D
Common Stock
141090
I
See footnote
Common Stock
141090
I
See footnote
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.7185. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.716. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust I.
The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust II.
/s/ R.A. Session II
2023-06-26